Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05937880Recruiting
Leflunomide for kids with stubborn Henoch-Schonlein purpura rash
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
Guangzhou, GuangdongAges 1–18 - NCT05939167RecruitingPhase 1/Phase 2
Stem cell treatment study for people with late-stage HIV
This Phase 1/2 study tests whether mesenchymal stem cells can help people with HIV who have lower immune cell counts. You would join a treatment plan and follow study rules closely, while the researchers track safety and early signs of benefit.
BeijingAges 18–65 - NCT05938478Recruiting
Pregnancy registry for outcomes after tralokinumab exposure
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
La Jolla, CaliforniaAges Any age - NCT05940272Recruiting
Communication training for doctors treating large B-cell lymphoma
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
New York, New YorkAges 18 years+ - NCT05942885Recruiting
Hypnosis for calming anxiety in lymphoma patients
This trial studies whether hypnosis can help reduce anxiety. It is meant for adults with certain types of lymphoma who are newly told their diagnosis and have anxiety symptoms.
Lyon, Pierre-BéniteAges 18 years+ - NCT05942625RecruitingPhase 1
Study of an experimental drug in healthy adults
This Phase 1 trial tests how safe and tolerable an experimental medicine (HS-10390) is in healthy adults, and how the body processes it. It is not for people with an illness, but for healthy volunteers to help researchers understand the drug before future studies.
Nanjing, JiangsuAges 18–45 - NCT05943496RecruitingPhase 1
Tafasitamab plus acalabrutinib and obinutuzumab for untreated CLL/SLL
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
Portland, OregonAges 18 years+ - NCT05943548Recruiting
Traditional healer support to help HIV reach low viral levels
This study tests whether support from traditional healers can help people with HIV get their viral load down to very low levels. You may be offered additional support and asked to attend clinic and nurse visits over 2 years.
MbararaAges 18 years+ - NCT05945524Recruiting
Study of how teclistamab works in multiple myeloma patients
This study looks closely at patients’ immune cells to understand why teclistamab helps in multiple myeloma. Your participation could help doctors better predict who benefits and how the treatment works.
Amiens, FranceAges 18 years+ - NCT05947136Recruiting
PASCA program study after stem cell transplant for myeloma
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
ÉpagnyAges 18–70 - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT05949944RecruitingPhase 1/Phase 2
Testing linperlisib plus CHOP for untreated peripheral T-cell lymphoma
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
Guangzhou, GuangdongAges 18 years+ - NCT05950997Recruiting
Test drug combo for newly diagnosed CLL in Chinese adults
This study tests acalabrutinib together with obinutuzumab in people with newly diagnosed chronic lymphocytic leukemia (CLL) to see how well the combination works. It may help by improving control of the cancer, but you’ll be closely monitored for side effects.
Nanjin, JiangsuAges 18 years+ - NCT05951517Recruiting
Mycophenolate for stubborn stomach Purpura (HSP) in children
This trial looks at whether mycophenolate mofetil can help children ages 3–18 who have Henoch-Schönlein purpura affecting the gut that does not improve with steroid treatment. It may help reduce serious stomach symptoms like severe belly pain, bleeding, or bowel problems.
Guangzhou, GuangdongAges 3–18 - NCT05951751Recruiting
Study of stopping mother-to-baby transmission after birth
This study tests a program meant to reduce how infections can pass from a mother to her baby during and after delivery. It enrolls mothers at selected maternity hospitals during a post-birth checkup.
Bobo-DioulassoAges Any age - NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05954416Recruiting
Study follow-up for rare skin and related genetic conditions
This study (a “cohort”) follows people with certain rare skin conditions over time. It helps doctors better understand these diseases and improve long-term care, and you may be asked to complete surveys.
BobignyAges Any age - NCT05955066RecruitingPhase 4
Testing a JAK inhibitor to help RA joint erosion heal
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
Hong Kong, Hong KongAges 18–65 - NCT05956041RecruitingPhase 2
Pembrolizumab and mogamulizumab for advanced relapsed skin lymphoma
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Ann Arbor, MichiganAges 18 years+ - NCT05956457Recruiting
Using wearable and PRO check-ins for relapsed myeloma
This study uses your self-reported symptoms (PRO) and wearable/device data to help improve care for people with relapsed multiple myeloma who are starting new treatment. It may help by providing insights about how you’re doing during therapy—without changing your cancer treatment in a study-specific way.
Seattle, WashingtonAges 18 years+ - NCT05957055RecruitingPhase 2
ADHD medicine compared for kids with type 1 diabetes
This Phase 2 study compares two ADHD medicines—lisdexamfetamine and methylphenidate—in children who have ADHD and type 1 diabetes. It’s designed to see which option works better and is safe/effective for managing ADHD without causing major problems for diabetes care.
Lodz, Łódź VoivodeshipAges 8 years–16.5 years - NCT05958719RecruitingPhase 2
Chidamide plus chemotherapy for new nodal TFH cell lymphoma
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05959720Recruiting
Teen-to-adult ALL study using a pediatric chemotherapy plan
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
São Paulo, São PauloAges 16–50 - NCT05959694RecruitingPhase 1/Phase 2
Study drug TQB3909 for CLL/SLL that keeps coming back
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
Anqing, AnhuiAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.